Thomas Sheung Chee Ng1,2, Daniel Procissi1,
Hargun Sohi1, Andrew A. Raubitschek3, Russell E. Jacobs1
1California Institute of Technology,
Pasadena, CA, United States; 2University of Southern California,
Los Angeles, CA, United States; 3Beckman Institute, City of Hope,
Duarte, CA, United States
IT-101
is a novel nanoparticle therapy that specifically targets the tumor mass. We
evaluated whether diffusion MR is sensitive to early IT-101 response in a
mouse model of lymphoma.